![Julie Feder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Julie Feder
Directeur Financier/CFO chez AURA BIOSCIENCES, INC.
Fortune : 100 586 $ au 30/06/2024
Profil
Julie B.
Feder is the Chief Financial Officer at Aura Biosciences, Inc. She previously held the same position at Verastem, Inc. and Clinton Health Access Initiative.
Prior to that, she worked as a Senior Manager at Deloitte & Touche LLP and as Vice President-Internal Audit at Genzyme Corp.
Feder received her undergraduate degree from Sy Syms School of Business.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
AURA BIOSCIENCES INC
0,03% | 20/03/2024 | 13 305 ( 0,03% ) | 100 586 $ | 30/06/2024 |
Postes actifs de Julie Feder
Sociétés | Poste | Début |
---|---|---|
AURA BIOSCIENCES, INC. | Directeur Financier/CFO | 01/08/2018 |
Anciens postes connus de Julie Feder
Sociétés | Poste | Fin |
---|---|---|
VERASTEM, INC. | Directeur Financier/CFO | 01/06/2018 |
Clinton Health Access Initiative
![]() Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Directeur Financier/CFO | 01/07/2017 |
Deloitte & Touche LLP
![]() Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2008 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - |
Formation de Julie Feder
Sy Syms School of Business | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
VERASTEM, INC. | Health Technology |
AURA BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Clinton Health Access Initiative
![]() Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Commercial Services |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Deloitte & Touche LLP
![]() Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |